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Abstract: 
This work demonstrated the feasibility of the extemporaneous preparation of maltodextrins 
orodispersible films (ODF) by hot-melt ram-extrusion 3D printing. This method consists of three 
simple technological operations which can be also implemented in a pharmacy setting. First, 10 
maltodextrins, drug, and other excipients are mixed in a mortar and wetted with the plasticizer (i.e. 
glycerine). Then, the mixture is fed in the chamber of the ram-extruder and heated. ODF are 
individually printed on the packaging material foil and sealed without further manipulations. The 
critical formulation attributes and process variables were investigated to define the processability 
space. In particular, the optimal conditions to print a mixture of maltodextrins/glycerine in 80/20 15 
w/w ratio resulted: heating temperature: 85°C; needle gauge: 18 G; needle-packaging material foil 
distance: 0.6 mm; maximum print rate: 50 mm/s; filling angle: 120°. The maximum drug loading 
was about 40%, when paracetamol was used as model drug. The compounded ODF complied with 
USP and Ph. Eur. specifications for disintegration time (< 1 min). The dissolution pattern of 
paracetamol overlapped with that obtained from ODF with a similar composition prepared by the 20 
consolidated solvent casting technique, demonstrating the suitability of the proposed technology. 
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1 Introduction 
Commercially available oral medicinal products do not satisfy all needs of special populations, such 
as dysphagics (Cilurzo et al., 2018), paediatrics (Visser et al., 2017), geriatrics (Scarpa et al., 2017) 30 
and patients with allergies or dietary restriction (Minghetti et al., 2015). In these cases, the drug has 
to be re-formulated or made from different inactive ingredients to comply the specific medical 
needs.  
When the required dose is not available, the most common solution, which implies to split a solid 
dosage form, often occurs in dose inaccurancy (Casiraghi et al., 2014; Somogyi et al., 2017). The 35 
possible alternative is to compound a personalized drug product, e.g. solutions, syrups, capsules and 
tablets, in pharmacy settings. Despite this approach allows personalizing the dose, issues related to 
possible inaccuracy are only partially solved. As an example, the use of spoons or syringes would 
not allow the precise withdraw of the exact volume of liquids. On the other hands, the 
administration of tablets and capsules, which overcomes this drawback, can be associated with 40 
swallowing problems or fear of chocking and, in these cases, the patient compliance and the 
therapeutic adherence remain quite low (Cilurzo et al., 2018). 
In the recent years, orodispersible dosage forms have been proposed in the personalization of the 
therapy (Visser et al., 2015), especially for children (Orlu et al., 2017) and elderly (Slavoka and 
Breitkreutz, 2015) due to the possibility of combining the advantages of solid dosage forms and 45 
liquid formulations. Despite both orodispersible tablets and films (ODF) can be currently 
compounded in pharmacy settings (Jha et al., 2011; Allen, 2016), the latter results are particular 
attractive since the dose is defined not only by the drug strength, but also by the dimensions of the 
ODF itself. In the selection of the appropriated manufacturing and/or compounding process, several 
technical and economic aspects have to be considered, e.g. the small batch production due limited 50 
number of dosage forms required for an individual patient, the cleaning procedure of the equipment 
to avoid the cross-contaminations, the number of critical process parameters to control  during the 
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preparation and, last but not least, the necessity of a moisture proof packaging to protect ODF over 
the shelf-life. 
In literature, both solvent casting and printing technologies have been proposed to prepare ODF. 55 
The former consist in a lab-coater apparatus that combines a doctor knife unit to  assure the 
uniformity of thickness, and therefore of the drug content, to an oven to dry the slurry. 
Nevertheless, the residual moisture content in ODF is one of the main critical limitation of this 
strategy due to the impact on the film mechanical properties and stability (Musazzi et al., 2018). As 
an alternative, the simplest  approach consists of depositing a known amount of a drug loaded 60 
polymeric slurry on a support, e.g. petri dish, flat moulds or unit-dose plate, drying in an oven and 
cutting the obtained film (Dinge and Nagarsenker, 2008, Liu et al., 2017; Foo et al., 2018;). In this 
case, the possible risks of dose inaccuracy are related to the lack of perfect alignment of the support 
base or the oven shelf that can cause the movement of the slurry and, therefore, a not-uniform film 
thickness. Ink-jet printing, which is based on the drug loading onto an edible film, is probably the 65 
widest explored printing technology to produce ODF. The feasibility of this approach was 
demonstrated with several drugs (Scarpa et al., 2017) also in fixed combinations (Thabet et al., 
2018). Moreover, inkjet printing can enable the simultaneous and independent dosing of drug 
combinations, as demonstrated using triiodothyronine and thyroxine, easily recognized by adding 
two different colouring agents (Alomari et al. 2018). The addition of a colouring agent to the ink 70 
can also permit the simple visualization of the uniformity of printed structures and, therefore, drug 
content (Vakili et al., 2016). Despite these advantages, this technology cannot be easily applied to 
load poorly soluble drugs, since inks need to be formulated case-by-case to avoid the drug 
sedimentation, which is the main source of dose inaccuracy. Hence some Scarpa and co-workers 
opts to formulate  not-aqueous solutions, nanosuspensions or lipidic inks (Scarpa et al., 2017). 75 
Alternatively, the melt ink-jet printing allows a good control of the drug solid state and film 
morphology (Içten et al., 2015; Içten et al., 2016) and the flexographic printing was also tested to 
impregnate placebo ODF with a precise dose of a drug (Janßen
 
 et al., 2013). 
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More recently, fused deposition modelling (FDM) 3D printing, which is usually explored to design 
solid oral dosage forms (Awad et al., 2018) with different geometries (Sadia et al., 2018) and 80 
release characteristics (Kadry et al., 2018) was also studied in the attempt to avoids the need of 
preformed films (Ehtezazi et al., 2018). Nevertheless, the application of such technology to the 
extemporaneous preparation of ODF could be very complicated because drug-loaded filaments have 
to be preliminarily produced by hot-melt extrusion (Cunha-Filho et al., 2017) or obtained by 
impregnation of commercial filament (Kadry et al., 2018) with all the limitation described by 85 
Fuenmayor and co-workers (2018). 
This work describes a novel approach to print ODF intended for personalized therapy. The basic 
idea of the proposed technology arose from the combination of a hot melt ram extruder, able to 
extrude a drug/polymer/plasticizer blend, and the typical aligned plate of 3D printers whose 
movements allow the deposition material of the desired dimensions and shape. Maltodextrins were 90 
tested as the main component of the formulation since the possibility to obtain ODF by hot-melt 
extrusion is documented (Cilurzo et al., 2008) as well as the feasibility to tune the ODF mechanical 
properties by varying the maltodextrins molecular weight and/or the plasticizer ratio (Cilurzo et al., 
2010; Cilurzo et al., 2011). 
 95 
2 Materials and methods 
2.1 Materials 
Maltodextrins with a dextrose equivalent (D.E.) equal to 6 (Glucidex
®
 IT6, MDX6) and 12 
(Glucidex
®
 IT12, MDX12) were kindly obtained by Roquette (France). Paracetamol (PAR), 
glycerine and titanium dioxide (TiO2) were purchased from Farmalabor (Italy). Span
®
 80 was 100 
supplied from Croda (Spain). Glycine (GLY) was purchased from ACEF. (Italy). All solvents were 
of analytical grade unless specified. 
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2.2 Rheological characterization of maltodextrin/plasticizer blends 
Compression tests – Tests were performed on 0.4 mm thick laminates made of MDX6 and glycerine 105 
in the 80/20 and 84/16 ratios in order to assess their softening temperature. Laminates were 
prepared by solvent casting technique by using a laboratory-coating unit Mathis LTE-S(M) 
(Swissland). MDX6 (75% w/w) and glycerine in water at 80 °C under stirring. After a rest period of 
at least 24 h to remove air bubbles, the aqueous dispersion was cast onto a silicone release liner 
with a 650 μm thickness. The coating rate was fixed at 1 m/min, and the cast dispersion was dried 110 
in the oven at 80 °C for 30 min with a horizontal air circulation speed of 1200 rpm. 
Laminates were placed in the rheometer (Physica MCR 300 rheometer, Anton Paar GmbH, Austria) 
at 50 °C, compressed with a normal force of 10 N using a 25 mm upper plate and heated at the 
heating rate of 5 °C/min. The softening temperature was expressed as the onset of the curve 
resulting from the analysis. 115 
Frequency sweep experiments - Tests were performed on selected ODF, among those reported in 
Table 1, from 100 to 0.1 Hz (angular frequency – ω of 620-0.628 s-1) in the strain-controlled mode 
using a plate-plate geometry, 25 mm diameter at the temperature of 80, 90, 100 and 110 °C 
(Physica MCR 300 rheometer, Anton Paar GmbH, Austria). The strain was set at 5% to be in the 
linear viscoelastic regime of the blends. In order to estimate a possible relationship between the 120 
rheological data and the feasibility to print the designed formulations, the shear viscosity at 1.1 s
-
1
shear rate was calculated according  to Cox-Merz rule. The shear rate value was also determined 
since it corresponds to the extrusion rate during the 3D printing of the ODF. 
 
2.3 Preparation of ODF 125 
Design of the printer - The printer was designed modifying a Cartesian FDM 3D printer (Futura 
Group Srl, Italy), as depicted in Figure 1. In particular, the apparatus used for the filament 
extrusion was replaced by in-house vertical ram extruder. The 60 mL extrudating chamber was 
thermostated in the range from 30 to 200 °C and ended with a Luer-lock system fitting 1.8 cm 
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length needles with a gauge ranging from 18 to 20 G. The melted materials extruded through the die 130 
was deposited on a 2020 cm aluminium packaging foil. This foil also consisted in the primary 
packaging of ODF. The ram speed and the chamber temperature were controlled by Repetier-Host 
2.0.1 software (Hotword GMBH, Germany); the film dimension and number per each print were 
designed by 3D builder (Microsoft, USA) and converted in G-code. Finally, ODF were sealed with 
another packaging foil without further manipulations. 135 
Preparation of the mixture for printed ODF - The mixtures were obtained by mixing the exactly 
weighted amount of each component in a mortar according to the composition reported in Table 1. 
The final weight of each mixture was about 10 g. 
Preparation of cast ODF - ODF containing 25% w/w paracetamol was also prepared by solvent 
casting technique and used as reference for dissolution studies. Briefly, an aqueous dispersion was 140 
prepared by mixing MDX6, glycerine, Span
®
 80 in distilled water at 80 °C under stirring. After at 
least 24 h of rest to remove air bubbles, the aqueous dispersion was cast onto a silicone release liner 
with a 150 μm thickness. The coating rate was fixed at 1 m/min, and the cast dispersion was dried 
in the oven at 80 °C for 30 min with a horizontal air circulation speed of 1200 rpm. The obtained 
cast ODF (formulation C1) had the following composition: 57 % w/w MDX6, 16 % w/w glycerine, 145 
2 % w/w Span
®
 80, and 25% w/w paracetamol. 
 
2.4 Physical characterization 
Film thickness – The film thickness was measured by using a micrometer MI 1000 µm 
(ChemInstruments, USA). 150 
Film stickiness – The ODF stickiness at different plasticizer contents was evaluated by the thumb 
tack test. Briefly, the thumb was pressed lightly on a film sample for a short time and, then, quickly 
withdrawn. By varying the pressure and time of contact and noting the difficulty of pulling the 
thumb from the adhesive, it is possible to perceive how easily, quickly and strongly the adhesive 
can form a bond with the thumb. All the tests were simultaneously performed and blind. The 155 
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stickiness of the ODF was expressed by the following score system: A (no sticky), B (sticky), and C 
(very sticky) (Musazzi et al., 2018). 
Tensile properties – Tests were conducted according to ASTM International Test Method for Thin 
Plastic Sheeting (D 882-02) using an Instron 5965 texture analyzer (Instron, UK), equipped with a 
50 N load cell. The film was cut into 8015 mm strips and equilibrated at 25±1 °C for 1 week. 160 
Each test strip was longitudinal by placed in the tensile grips on the texture analyzer. Initial grip 
separation and the crosshead speed were 20 mm and 12.5 mm/min, respectively. The test was 
considered concluded at the film break. The following parameters were determined: 
Tensile strength (TS) was calculated by dividing the maximum load by the original cross-sectional 
area of the specimen. 165 
Percent elongation at break (E%) was calculated according to the following equation: 
100%
0
0 


L
LL
E  
where L0 is the initial gage length of the specimen and L is the length at the rupture. 
Elastic modulus or Young’s modulus (Y) was calculated as the slope of the linear portion of the 
stress-strain curve. 170 
Tensile energy to break (TBE) was defined by the area under the stress-strain curve. The results 
were expressed in MPa. 
 
2.5 Loss of drying 
The loss on drying (LOD) in films was determined gravimetrically by using a thermobalance 175 
(Gilbertini, Italy). Film samples were kept at 105 °C until constant weight. 
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2.6 Disintegration test 
The disintegration test was carried out in water according to specifications of the monograph on 
“Disintegration of tablets and capsules” reported in the Ph. Eur. The results complied the Ph. Eur. 180 
requirement for orodispersible tablets if the disintegration time was lower than 3 min. 
 
2.7 Drug content 
A 32 cm loaded ODF was dissolved in 100 mL purified water, sonicated for 10 min and diluted 
1:10. Paracetamol content was determined spectrophotometrically at 243 nm (UV-Vis spectrometer, 185 
Lambda 25, Perkin Elmer, Italy). The calibration curves ranged from 10 to 100 µg/mL (R
2
 < 0.999). 
 
2.8 In vitro dissolution test 
The in vitro dissolution test was carried out in a Ph. Eur. basket dissolution apparatus using  32 cm 
samples of paracetamol loaded ODF. The dissolution medium was 900 mL freshly deionized water, 190 
maintained at 37±1 °C and stirred at 50 rpm. Paracetamol concentrations were assayed 
spectrophotometrically at 243 nm (UV-Vis spectrometer, Lambda 25, Perkin Elmer, Italy) every 2 
min and the calibration curve was in the range of 10-100 µg/mL (R
2
 < 0.999). A loaded ODF 
prepared by solvent casting technique (25% w/w) was used as control. The results were expressed 
as the mean and standard deviation values of four replicas for each tested formulation. 195 
 
3 Results and Discussion 
 
3.1 Rheological characterizations  
In order to determine the temperature range suitable for frequency sweep experiments, preliminary 200 
compression tests were performed on laminates made of MDX6. This material was supposed to 
present the highest softening temperature, having the highest Mw. The softening temperatures of 
laminates containing 20% w/w or 16% w/w glycerine were at about 79.5 °C and 99.7 °C, 
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respectively. Therefore, the temperature range of frequency sweep experiments was set in the range 
80-110 °C. The results evidenced that all tested samples did not present a pseudo-plastic behaviour, 205 
i.e. no plateau viscosity was reached at low angular frequency, probably due to the high number of 
interactions arising among –OH groups. As an example, the rheological pattern of formulation 1 
(MDX6/glycerine ratio: 80/20) is exemplified in Figure 2.  
To estimate the possible behaviour of formulations upon printing, the shear viscosity was also 
measured The amount of the plasticizer was more relevant than the MDX molecular weight in 210 
determining the viscosity of the blend (Table 2). Furthermore, in agreement with the previous DSC 
data (Selmin et al., 2015), glycine significantly ameliorated the fluidity of the melted blends (Table 
2). 
 
3.2 Set-up of printing operative conditions 215 
On the bases of the frequency sweep data  the  temperature for the hot-melt ram extrusion of 
formulations containing the 20% and 16% w/w glycerine was set at 85 °C and 95 °C, respectively. 
Moreover, based on the results of compression tests, a time lapse of 10 min between the mixture 
loading and the beginning of the ram movement was established to permit the complete melting of 
the formulation. The set-up of the operative conditions, the needle inner diameter, the relative 220 
distance between the extruder needle and the mobile plate, the speed of the mobile plate and the 
filling angle, was defined by using Formulation 4 and Formulation 9 (Table 1). In particular. 
Formulation 9, having the highest glycerine content, was selected to check the impact of fluidity of 
the melt on printability. Conversely, Formulation 4 was tested as a worst case since it contained the 
lowest amount of glycerine, glycine as non-traditional plasticizer and TiO2 a very fine inert powder 225 
usually used to mask possible visual defects of ODF. 
First, the extrusion of formulation 4 at the extrusion 1.1 s
-1
 shear rate was possible only using the 18 
gauge-needle (inner diameter 0.838 mm). Secondly, the suitable deposition of the melted blend on 
packaging foil was possible only setting the distance from the needle tip to the surface of the 
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packaging material foilin the range of 0.5-0.8 mm. Indeed, at distances lower than 0.5 mm, the 230 
needle tip scratched the film causing irregularity and roughness on the surface, whilst at distances 
higher than 0.8 mm, the extruded material could not deposit in a consistent and uniform way. 
Thirdly, the impact of print rate on the film formation was investigated in the 10-50 mm/s range 
increasing the extrusion shear rate, accordingly. The maximum rate which allowed the deposition of 
a filament with a uniform diameter, resulted 12 mm/s and 50 mm/s for formulations 4 and 9, 235 
respectively. 
Finally, the effect of the filling angle on the homogeneity and tensile properties of films was studied 
by printing at 90°, 120° 135°, 150° and 180° with respect to the X-axis of the packaging material 
foil (Figure 3). The results indicated that the filling angle did not affect the film appearance. In the 
case of formulation 4, some small differences were noticed in the main descriptors of the tensile 240 
property (Table 3), suggesting an influence of the filling angle on the film inner organization. 
Indeed, due to the peculiar preparation process, it was possible to speculate that the printed films 
had some high-dense zones at the deposition lines of extruded materials and some low-dense zones 
between the previous ones due to the reorganization of the melted materials after deposition. 
Therefore, toughness (e.g., TS and TBE) reached the highest values when the highly dense zones of 245 
the films were parallel to the tensile force applied (i.e., 180°). On the contrary, the lowest TBE 
values were determined when the dense material zones were perpendicular (i.e., 90°) since the film 
resistance to deformation was mainly limited by thin and low-dense zones, which were expected to 
be mechanically weak. Interestingly, ODF printed at the filling angle of 120° showed the highest 
field of elasticity (i.e., the lowest Y values) and a satisfactory toughness probably due to a 250 
cooperation between high-dense and low-dense zones during the elongation phase. A similar trend 
was observed in the case of formulation 9 printed at 120° confirming that the orientation of the 
high-dense and low-dense zones influenced the tensile properties (Table 3). 
The comparison of the tensile data on these two formulations evidenced an anomalous result 
considering the plasticizer content. Indeed, the higher glycerine concentration, the lower the 255 
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ductility (E% values) and the tenacity of the film (TS). This feature can be attributed to glycine and 
TiO2, which actas non-traditional plasticizers (Selmin et al., 2015) and nanofiller of maltodextrins 
(Franceschini et al., 2016), respectively. 
On the bases of the obtained data, the following process parameters were set and used for further 
studies: 260 
- needle gauge: 18; 
- needle-to-packaging material foil distance: 0.6 mm; 
- print rate: 12 mm/s; 
- ram rate: 10 mm/s (corresponding to a calculated shear rate of the melted mixture of 1.1 s-1); 
- filling angle: 120°. 265 
 
3.3 ODF characterization 
All printed films presented relatively low LOD values (Table 1) if compared to other formulations 
(Musazzi, 2018) and the thickness in the 150-250 m range was considered suitable for patient’s 
handling. Moreover, ODF dissolved within 3 min complying with Ph. Eur. specifications for 270 
orodispersible dosage forms (Ph. Eur., 2018a). 
Although the tensile properties and stickiness of printed ODF are not as critical as for those 
industrially produced by solvent casting technique, which are rolled up on reels and cut, their 
investigation is worthy of interest to avoid problems during  the patient’s handling.  
The data obtained during the definition of the process parameters evidenced an impact of mixture 275 
composition on the printability. The formulations containing 16% w/w glycerine were not 
consistently extruded through a 18 gauge-needle unless glycine was also added at the concentration 
of 2.5% or 1.25% w/w glycine for MDX6 (formulations 3 and 4) and MDX12 (formulation 6), 
respectively. These results suggested that the shear viscosity, calculated at 1.1 s
-1
 of shear rate, 
might be lower than 7 kPa*s. Nevertheless, formulations made of MDX12 (formulations 6 and 7) 280 
were stickier than those based on MDX6 (formulations 3 and 4) (Table 1), confirming the relevance 
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of the maltodextrin molecular weight. Moreover, in ODF prepared with MDX6 and the highest 
glycerine concentration, the concomitant presence of glycine increased the elasticity in a 
concentration-dependent way and had a negative impact on toughness. Indeed TS, TBE and Y 
values (Table 4) decreased in the following order: formulation 9 > formulation 11 > formulation 12 285 
(p < 0.05). 
As expected, the addition of TiO2 (see formulation 3 vs. formulation 4; formulation 10 vs. 
formulation 9, Table 4) decreased the Y values suggesting that the peeling of film from the 
packaging foil should be easier.  
Based on these results, some generic considerations on preparation methods and the ODF 290 
characteristics can be drawn. First, the disintegration time of printed ODF is more similar to that of 
films with similar composition, but prepared by hot-melt extrusion (≥ 45 s), rather than by solvent 
casting (≈ 10 s) (Cilurzo et al., 2008). Furthermore, the disintegration times (Table 1) were closed 
to the results reported for film prepared by FDM 3D printing (Ehtezazi et al., 2018; Jamroz et al., 
2017). Secondly, the printed ODF showed weaker tensile properties than the parent casted and hot-295 
melt extruded ODF probably because the peculiar deposition of melted material do not allow 
obtaining a uniform film in comparison to extrusion. As a consequence, the TS values of extruded 
ODF composed by MDX12, glycerine and cellulose microcrystalline in the 66:22:11 ratio (Cilurzo 
et al., 2008) resulted 5-fold higher than formulation 9. Moreover, the solvent casting technique 
allowed to obtain higher cohesion of the ODF matrix, since the maltodextrin chains and glycerine 300 
could rearrange in a dense structure during the solvent evaporation phase, resulting in a film with 
suitable mechanical properties even at thinner thickness.  
It is noteworthy that the proposed maltodextrin ODF showed a higher elasticity and a lower 
toughness than that of PVA-based ones (Jamroz et al., 2017), while the overall tensile properties 
were similar to those of films made of PEO and starch (Ehtezazi et al., 2018). 305 
When paracetamol was loaded as model drug, ODF appeared whitish without significant 
differences in thickness and weight (Table 5) or in the disintegration time with respect to the 
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corresponding placebo formulations (Table 1). Paracetamol could be loaded in ODF up to 35% 
w/w (Table 5) and in all cases the uniformity of dosage units was within the limit (L1 ± 15%) set by 
the European Pharmacopoeia (Ph. Eur., 2018b). 310 
In agreement with the literature data (Musazzi et al., 2018), the paracetamol loaded into ODF 
altered the tensile properties (Table 4) increasing the ODF toughness (e.g., TS; p < 0.01) and, 
consequently, decreasing its ductility (i.e., E%; p < 0.02) with respect to placebo formulations (i.e., 
formulations 4 and 9). However, this effect was not related to the paracetamol content  since  no 
significant differences in terms of TS, Y and E% values (formulations 13-15) were observed. 315 
However, a slight decrease of TBE values observed in 35% w/w drug loaded ODF (p < 0.01) 
suggested that a high payload can create inhomogeneous spot in the inner structure of an ODF 
causing the alterations of its mechanical properties (Musazzi et al., 2018). 
As shown in the dissolution profiles reported in Figure 4, about 80% of paracetamol was dissolved 
within 6 min so that the proposed printed ODF can be classified as very rapidly dissolving dosage 320 
forms according to the FDA (FDA, 2017). However, slight differences were observed depending of 
plasticizer content since ODF containing 20% w/w glycerine dissolved faster (t80% ≤ 2 min) than 
those with 16% (t80% ≈ 6 min). The dissolution profiles resulted superimposable in comparison to 
Formulation C1 produced by casting technique. These results confirmed the ability of maltodextrins 
to improve the dissolution rate of several active ingredients such as piroxicam (Cilurzo et al., 2008), 325 
diclofenac (Cilurzo et al., 2011) and in some cases to enhance the mucosae permeation also in 
comparison with other film forming materials used to prepare ODF as demonstrated in the case of 
sumatriptan (Soni et al., 2015).  
 
4 Conclusions 330 
The feasibility to prepare MDX-ODF by hot melt ram extrusion 3D printing was demonstrated. The 
proposed preparation method consists of a simple procedure involving the mixing of the active 
ingredient with MDX and other excipients, the wetting of the mixed powders by glycerine, the 
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loading into the ram extruder and the printing of the single dosage form directly on the packaging 
foil. This aspect is relevant since the printed ODF can be sealed with another packaging foil 335 
avoiding handling of the dosage form. The drug strength can be easily defined designing the size of 
ODF. The uniformity of drug amount per unit of these medicinal products should be guarantee 
aiming to serve the interest of patients.  Conversely to the industrial products, the drug strenght 
cannot be quantified due to the limitation of pharmacy equipment, time and costs (Resolution 
CM/Res(2016)1). As proposed for ink-jet printing, the drug homogeneity in the wet mixture could 340 
be indirectly checked by adding small amounts of colourant during the mixing, which is the most 
critical operation. Indeed, variation in ODF thickness and dimensions, can be indirectly determined 
gravimetrically.  
The proposed method also appears to be more versatile than FDM 3Dprinting, where it is necessary 
to produce drug loaded filaments, to obtain the final object. With respect to the ink-jet printing 345 
technologies, the proposed approach presents the advantage to not require the preliminary 
preparation of placebo ODF. Moreover, avoiding the use of solvents, this method also reduces the 
risks of drug polymorphism. Based on this evaluation, we consider this method as a good 
opportunity to extemporaneously prepare tailored solid dosage forms in hospital and community 
pharmacies. 350 
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Figure captions 
 
Figure 1 – The main features of hot melt ram extrusion 3D printer. 
 355 
Figure 2 – Frequency sweeps curves of formulation 9 performed at 80 °C, 90 °C, and 110 °C. 
 
Figure 3 – Schemes of filling angles of 3D printed films. 
 
Figure 4 – Dissolution profiles of paracetamol from ODF obtained by 3D printing (formulations 360 
F8, F13-15) and casting solvent technology (formulation C1) (mean ± St.Dev., n = 4). 
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Table 1 – Composition of placebo and paracetamol (PAR) loaded ODF obtained by 3D printing. The main components were 
maltodextrins with a dextrose equivalent of 6 (MDX6) and 12 (MDX12), glycerine (GLN), glycine (GLY) and titanium dioxide 
(TiO2). Loss of drying (LOD) and disintegration time (Disgr) are enlisted.  The ODF stickiness is expressed by the following score 
system: A (no sticky), B (sticky), and C (very sticky). 
 
Form 
ODF composition (%, w/w) LOD 
(%, w/w) 
Stickiness 
(A, B, C) 
Disgr. 
(s) MDX6 MDX12 GLN GLY PAR TiO2 
1 84.00 - 16.00 - - - -* -* -* 
2 82.75 - 16.00 1.25 - - -* -* -* 
3 81.50 - 16.00 2.50 - - 7.8±2.6 A 86±33 
4 81.40 - 16.00 2.50 - 0.10 10.9±2.8 A 73±15 
5 - 84.00 16.00 - - - -* -* -* 
6 - 83.90 16.00 1.25 - 0.10 -* B 90±10 
7 - 81.40 16.00 2.50 - 0.10 -* C 103±7 
8 61.60 - 11.60 1.80 25.00 - 8.1±1.4 A 75±5 
9 80.00 - 20.00 - - - 7.1±2.2 A 53±35 
10 79.90 - 20.00 - - 0.10 5.6±1.4 A 65±28 
11 78.75 - 20.00 1.25 - - 5.7±0.9 B 111±29 
12 77.50 - 20.00 2.50 - - 8.9±1.5 C 96±46 
13 70.00 - 17.50 - 12.50 - 7.5±1.7 A 75±29 
14 60.00 - 15.00 - 25.00 - 7.3±1.7 A 34±14 
15 50.00 - 12.50 - 37.50 - 4.8±1.2 A 42±2 
*: not determinable 
Table(s)
Table 2 – Shear viscosity values () of selected formulations calculated at the 1.1 s-1 shear rate 
and different temperatures. Tests were carried out on films made of maltodextrins with a 
dextrose equivalent of 6 (MDX6) or 12 (MDX12) and plasticized by glycerine (GLN) or glycine 
(GLY)  
Form. 
Composition (%, w/w) T 
(°C) 
η (Pa*s) 
MDX6 MDX12 GLN GLY 
1 84.00  16.00  
100 21000 
110 11600 
2 82.75  16.00 1.25 
90 7270 
100 7140 
110 6260 
3 81.50  16.00 2.50 
80 36370 
90 14480 
100 4030 
110 665 
5  84.00 16.00  
80 39960 
90 19680 
100 3470 
110 2860 
9 80.00  20.00  
80 14800 
90 3200 
100 2430 
110 540 
11 78.75  20.00 1.25 
80 5980 
90 4015 
100 1445 
110 513 
12 77.50  20.00 2.50 
80 8350 
90 5450 
100 1850 
110 800 
  
Table 3 – Tensile properties of formulation 4 (16% w/w glycerine) and 9 (20% w/w glycerine) 
printed at different filling angles (mean ± St.Dev., n = 5).  
Form. 
Filling 
angle 
TS 
(MPa) 
Y 
(MPa) 
E% 
(%) 
TBE 
(MPa) 
4 
90° 0.07±0.01 1.29±0.26 441±166 0.17±0.09 
120° 0.06±0.01 0.82±0.30 992±83 0.35±0.05 
135° 0.06±0.01 0.84±0.20 705±118 0.25±0.03 
150° 0.07±0.01 1.17±0.14 602±145 0.29±0.04 
180° 0.11±0.01 1.90±0.09 591±65 0.47±0.06 
9 
90° 0.37±0.15 8.07±4.69 127±56 0.38±0.14 
120° 0.19±0.05 2.76±1.69 431±155 0.66±0.12 
135° 0.48±0.19 7.62±2.59 139±74 0.41±0.07 
150° 0.45±0.10 10.19±2.91 180±53 0.51±0.09 
180° 0.38±0.20 7.53±2.73 184±88 0.44±0.15 
  
Table 4 – Tensile properties of printed ODF (mean ± St.Dev., n = 5). 
Form. 
TS 
(MPa) 
Y 
(MPa) 
E% 
(%) 
TBE 
(MPa) 
1 -* -* -* -* 
2 -* -* -* -* 
3 0.09±0.05 2.44±0.1.87 > 1000 0.38±0.17 
4 0.06±0.01 0.82±0.30 992±83 0.35±0.05 
5 -* -* -* -* 
6 -* -* -* -* 
7 -* -* -* -* 
8 0.75±0.12 23.13±1.72 71±15 0.30±0.07 
9 0.19±0.05 2.76±1.69 431±155 0.66±0.12 
10 0.05±0.03 0.81±0.47 312±146 0.05±0.01 
11 0.09±0.01 1.37±0.68 423±60 0.32±0.29 
12 0.01±0.01 0.13±0.01 414±76 0.02±0.01 
13 0.53±0.15 10.91±6.36 142±34 0.56±0.12 
14 0.43±0.04 8.83±2.06 160±55 0.51±0.16 
15 0.43±0.10 8.68±4.07 86±24 0.28±0.06 
*: not determinable 
  
Table 5 – Weight and paracetamol (PAR) content of ODF prepared by 3D printing (mean ± 
St.Dev., n = 3). 
Formulation 
ODF weight 
(mg) 
Drug content 
(mg) (%, w/w) 
8 233±45 73.56±3.90 23.49±0.23 
13 175±57 22.06±6.87 11.83±0.36 
14 215±4 48.94±8.96 25.10±1.31 
15 159±15 48.91±5.76 35.76±0.29 
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